Skip to main content
ADGM
NASDAQ Industrial Applications And Services

Adagio Medical Reports Q1 Results, Highlights Strong FULCRUM-VT Trial Data & $31M Warrant Potential

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.91
Mkt Cap
$20.878M
52W Low
$0.74
52W High
$2.582
52W Position info
23% above low
Off High info
65% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ADGM sits 23% above its 52-week low of $0.74.

Summary

Adagio Medical reported Q1 2026 results with ongoing losses and low cash, but highlighted pivotal positive clinical trial data and FDA approval for its next-gen system, alongside potential for $31 million from warrant exercises.


Key Events · Earnings and Guidance · ADGM

  • Q1 2026 Financial Results

    Reported nil revenue and a net loss of $7.0 million for the first quarter ended March 31, 2026, compared to a $7.7 million net loss in Q1 2025.

  • Cash Position and Warrant Potential

    Cash and cash equivalents stood at $12.9 million as of March 31, 2026. The company noted potential for up to an additional $31 million in gross proceeds from the cash exercise of milestone-based warrants.

  • Pivotal FULCRUM-VT Trial Results

    Announced positive late-breaking pivotal results from the FULCRUM-VT trial, demonstrating 84% freedom from implantable cardioverter defibrillator (ICD) shock at six months and a promising safety profile.

  • FDA IDE Approval for Next-Gen System

    Received FDA Investigational Device Exemption (IDE) approval to expand the FULCRUM-VT trial to evaluate the next-generation vCLAS Ultra System.


Analysis · ADGM · Industrial Applications And Services

Adagio Medical reported Q1 2026 financial results, showing continued nil revenue and a net loss of $7.0 million, with cash and cash equivalents at $12.9 million. This cash position provides a short runway, especially given the prior 'going concern' warning. However, the filing also highlights significant positive clinical progress, including pivotal FULCRUM-VT trial results demonstrating 84% freedom from ICD shock and FDA IDE approval for its next-generation vCLAS Ultra System. These clinical advancements are critical for the company's path to PMA approval and commercialization, which could unlock up to $31 million in additional gross proceeds from milestone-based warrant exercises, significantly extending its financial runway.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADGM was trading at $0.91 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $20.9M. The 52-week trading range was $0.74 to $2.58. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADGM - Latest Insights

ADGM
Nov 10, 2026, 5:30 PM EST
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $1.84
Real-time Price: $1.74 info
Change: -$0.1031 (-6%) info
Market Cap: $1.765M info
ADGM
Oct 01, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1535
Real-time Price: $1.74 info
Change: Reverse Stock Split info
Market Cap: $1.765M info
ADGM
Oct 01, 2026, 4:54 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.1544
Real-time Price: $1.74 info
Change: Reverse Stock Split info
Market Cap: $1.765M info
ADGM
Sep 23, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $0.489
Real-time Price: $1.74 info
Change: Reverse Stock Split info
Market Cap: $1.765M info
ADGM
Aug 13, 2026, 4:37 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6901
Real-time Price: $1.74 info
Change: Reverse Stock Split info
Market Cap: $1.765M info